Investor Hub
We are the world's first molecular MRI developer.
We are advancing our MagSense® imaging agent portfolio in clinical development to change the way we look at cancer.
Imagion Biosystems’ innovative medical imaging technology uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Our proprietary MagSense® technology is non-invasive and non-radioactive, providing more specific and accurate detection of cancer than current imaging technologies.
We have multiple commercial opportunities with our SPIONS (superparamagnetic iron oxide nanoparticles) including our proprietary MagSense® imaging technology.
Join our interactive Investor Hub
NEW! Engage with us directly by asking questions, watching video summaries, and be part of our shareholder community.
Investment Highlights
Listed on the ASX: June 2017
R&D operations: San Diego
Registered office: Melbourne
A clinical stage radiopharamaceutical company developing bio-safe, molecularly targeted MRI contrast agents.
- MagSense: SPIONS coated for biocompatibility and targeted by conjugated antibodies to detect cancer tumors
Earlier, more specific detection of cancers
- One in three people impacted by cancer
- Over $100B spent annual in cancer diagnosis but still unable to noninvasively diagnosis tumors
- Current medical imaging technologies invented more than 50 years ago
MagSense® technology will transform cancer diagnosis
- Does not require radioactivity
- Uses bio-safe superparamagnetic nanoparticles
- Targeting moieties include antibodies, antibody fragments, peptides, or small molecules
Multiple revenue opportunities
- High gross-margin proprietary molecular imaging agents
- Other biomedical applications enabled with customer supply agreements in place for use in their medical products
Strong leadership and advisory board
- Experienced and skill diverse board of directors and management team
- Scientific advisory board with collective expertise in oncology, medical imaging, nanotechnology and clinical trial design
Investment Quick Links
The Annual Report is a concise document which includes highlights of the relevant fiscal year’s progress, an update of our products in
development, an overview of operations and summary financial data.
Check out our latest presentation decks:
Before downloading, printing or viewing the Prospectus, please carefully read this information. By accessing the Prospectus (by clicking on the link below) you agree to and acknowledge that you have read and accept these terms and conditions of access. The information on this page is not part of the Prospectus. If you do not understand it, you should consult your professional adviser without delay.
Important Notice
Imagion Biosystems Limited (ACN 616 305 027) (Company) has lodged a prospectus dated 14 October 2024 (Prospectus) with the Australian Securities and Investments Commission (ASIC) for an offer of up to 1,000 fully paid ordinary shares in the capital of the Company (Shares) at an issue price of $0.033 per Share to raise up to $33 (before expenses) (Offer).
The Prospectus is an important document which should be read in its entirety. If, after reading the Prospectus you have questions about the Offer or any other matter, please contact your professional advisers without delay.
Neither ASIC nor ASX Limited, nor any of their respective officers, take any responsibility for the contents of the Prospectus or the merits of the investment to which the Prospectus relates.
The electronic copy of the Prospectus available on this website does not constitute an offer of, or an invitation to subscribe for, any securities. You may print out a hard copy of the Prospectus from this website or copy the electronic Prospectus on this website into an electronic file for your personal use only. You must not alter the contents of this electronic file in any way.
Alternatively, you may obtain a hard copy of the Prospectus free of charge by contacting the Company by phone on +61 3 9692 7222 during office hours or by emailing the Company at investor@imagionbio.com.
To the extent permitted by law, the Company is not liable for any loss incurred from accessing or downloading the Prospectus from this website, including, but not limited to, data corruption or download.
Applications
The Offer is only being extended to specific parties on invitation by the Company. Applications for Shares must be made by investors at the direction of the Company and must be made using the application form to be provided by the Company and attached to or accompanying the Prospectus. An application form and instructions on how to apply for Shares will only be provided to those specific parties invited to participate by the Company.
The Corporations Act 2001 (Cth) prohibits any person from passing onto another person an Acceptance Form unless it is attached to or accompanied by a complete and unaltered version of a prospectus.
The Company reserves the right not to accept Acceptance Form or payment of application monies from a person if it has reason to believe that when that person was given access to the electronic Acceptance Form, it was not provided together with the electronic Prospectus and any relevant supplementary or replacement prospectus or any of those documents were incomplete or altered.
If an Acceptance Form is not completed correctly, or if the accompanying payment is the wrong amount, the Company may, in its discretion, still treat the Acceptance Form to be valid. The Company’s decision to treat an acceptance as valid, and how to construe, amend or complete the Acceptance Form, will be final.
No Advice
Nothing contained on this website or in the Prospectus constitutes investment, legal, business, tax or other advice. In particular, the information on this website and in the Prospectus does not take into account your financial or investment objectives, financial situation or particular needs. In making an investment decision, you must rely on your own examination of the Company, the securities being offered for and the terms of the offering, including the merits and risks involved. You should consult your professional advisers for investment, legal, business, tax or other advice.
Persons to whom Offer is available
For legal reasons, the electronic version of the Prospectus accessible through this website is available to persons accessing this website from within Australia only. If you are accessing this website from anywhere outside Australia, please do not download the electronic version of the Prospectus.
The Prospectus does not constitute an offer, or invitation to apply for, of securities in any jurisdiction where, or to any person to whom, it would not be lawful to issue the Prospectus or to make the offer or invitation. It is the responsibility of any applicant outside Australia to ensure compliance with all laws of any country relevant to their applications, and any such applicant should consult their professional advisers as to whether any government or other consents are required, or whether any formalities need to be observed to enable them to apply for and be allotted any securities.
It is not practicable for the Company to comply generally with the securities laws of overseas jurisdictions having regard to the number of overseas shareholders, the number and value of securities those shareholders would be offered and the cost of complying with regulatory requirements in each relevant jurisdiction. Accordingly, the offer pursuant to the Prospectus is only being extended and securities will only be issued to shareholders with a registered address in Australia.
Acknowledgement
By clicking “I Accept” below, you acknowledge and agree that:
- You have read and understood the above terms and conditions to access the electronic version of the Prospectus;
- You are an Australian resident and you are requesting a copy of the Prospectus from within Australia;
OR
If you are a non-Australian resident, you have consulted your professional adviser as to whether any governmental or other consents are required or whether any other formalities need to be considered and followed before accessing the Prospectus; and
- You will not pass onto any other person the Acceptance Form unless it is attached to or accompanied by the complete and unaltered electronic version of the Prospectus.
By accessing the Prospectus (by clicking on the link below) you agree to and acknowledge that you have read and accept these terms and conditions of access.
☑ Click to accept terms & conditions and access Prospectus >>
View Consent of Legal Advisers
Latest News
Corporate Update – IND for MagSense® HER2 Phase 2 Study Immediate Priority
Corporate Updates: $3M fundraising led by CPS Capital to be completed in early December Filing of IND for MagSense® HER2 Phase 2 Study Immediate Priority
Successful Placement of A$3M
Imagion Biosystems (ASX: IBX) (Company), is pleased to announce the Company has received $3 million of firm commitments through a highly successful capital raising. The
[Video] Shareholder Webinar Recording | August 15, 2024
Open a copy of this presentation deck from our ASX announcement HERE. Video transcript: Mel: Good morning, everyone. Thank you for attending the investor presentation
Investor Services
Investors seeking information regarding their shareholding or dividends or wishing to advise of a change of address should contact Boardroom Pty Limited at:
Boardroom Pty Limited
Level 12, 225 George Street,
Sydney, NSW, 2000
Telephone: (02) 9290 9600 Facsimile: (02) 9279 0664 or
Visit the online service at www.boardroomlimited.com.au
Boardroom Pty Limited has an online service for investors called InvestorServe. This enables investors to make online changes, view balances and transaction history, as well as obtain information about recent dividend payments and download various forms to assist in the management of their holding.
To request listed option conversion forms, please email Boardroom at: corporateactions@boardroomlimited.com.au